Proceedings of the Oxygen Homeostasis/Hypoxia Meeting

Cancer Research

Volumn 64, Issue 9, 2004, Pages 3350-3356

  Kaufman, Bennett ^a   Scharf, Orit ^a   Arbeit, Jeffrey ^b   Ashcroft, Margaret ^c   Brown, J Martin ^d   Bruick, Richard K ^e   Chapman, J Donald ^f   Evans, Sydney M ^g   Giaccia, Amato J ^d   Harris, Adrian L ^h   Huang, Eric ⁱ   Johnson, Randall ^r   Kaelin Jr , William ^j   Koch, Cameron J ^g   Maxwell, Patrick ^h   Mitchell, James ⁱ   Neckers, Len ⁱ   Powis, Garth ^k   Rajendran, Joseph ^l   Semenza, Gregg L ^m   Simons, Jonathan ⁿ   Storkebaum, Erik ^o   Welch, Michael J ^p   Whitelaw, Murray ^q   Melillo, Giovanni ^g   Ivy, S Percy ⁱ   more..

^a TRI Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k UNIVERSITY OF ARIZONA   (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

^m JOHNS HOPKINS UNIVERSITY   (United States)

ⁿ EMORY UNIVERSITY   (United States)

^o UNIVERSITY OF LEUVEN   (Belgium)

^p WASHINGTON UNIVERSITY   (United States)

^q UNIVERSITY OF ADELAIDE   (Australia)

^r UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OXYGEN;

CANCER RESEARCH; CLINICAL RESEARCH; CONFERENCE PAPER; COOPERATION; DRUG RESEARCH; DRUG TARGETING; HEALTH CARE ORGANIZATION; HOMEOSTASIS; HUMAN; HYPOXIA; IMAGING SYSTEM; NONHUMAN; PRIORITY JOURNAL; SYMPOSIUM; UNITED STATES;

ANIMALS; CELL HYPOXIA; HOMEOSTASIS; HUMANS; NEOPLASMS; OXYGEN;

EID: 2342623476     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2611     Document Type: Conference Paper

References (79)

1. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
2. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001;18:243-59.
3. Guppy M. The hypoxic core: a possible answer to the cancer paradox. Biochem Biophys Res Commun 2002;299:676-80.
4. Vaupel P, Thews O, Kelleher DK, Hoeckel M. Current status of knowledge and critical issues in tumor oxygenation. Results from 25 years research in tumor pathophysiology. Adv Exp Med Biol 1998;454:591-602.
5. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000;48:919-22.
6. 2 study. Am J Clin Oncol 2001;24:458-61.
7. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-7.
8. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
9. Brown JM, QT Le, QT. Tumor hypoxia is important in radiotherapy, but how should we measure it? Int J Radiat Oncol Biol Phys 2002;54:1299-301.
10. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002;7:492-508.
11. Janssen HL, Haustermans KM, Sprong D, et al. HIF-1A, pimonidazole, and iodode-oxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 2002;54:1537-49.
12. Semenza GL. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 2003; 3:721-32.
13. 2 tension. Proc Natl Acad Sci USA 1995;92:5510-4.
14. 2 sensing. Science (Wash DC) 2001;292: 464-8.
15. 2-regulated prolyl hydroxylation. Science (Wash DC) 2001;292:468-72.
16. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 2000;14:34-44.
17. Zundel W, Schindler C, Hass-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000;14:391-6.
18. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (Lond.) 1999;399:271-5.
19. 18F-EF5. Eur J Nucl Med Mol Imaging 2003; 30:259-66.
20. Yang B, Keshelava N, Anderson CP, Reynolds CP. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine. Cancer Res 2003;63:1520-6.
21. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14.
22. Koumenis C, Alarcon A, Hammond E, et al. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 2001;21:1297-310.
23. Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ. Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 2002;22:1834-43.
24. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002;64:993-8.
25. Semenza GL. Physiology meets biophysics: visualizing the interaction of hypoxia-inducible factor 1α with p300 and CBP. Proc Natl Acad Sci USA 2002;99:11570-2.
26. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-7.
27. Buchler P, Reber HA, Buchler M, et al. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 2003;26: 56-64.
28. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002;16:1466-71.
29. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science (Wash. DC) 2002;295: 858-61.
30. Lando D, Gorman JJ, Whitelaw ML, Peet DJ. Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation. Eur J Biochem 2003;270:781-90.
31. Maxwell PH, Pugh CW, Ratcliffe PJ. The pVHL-HIF-1 system, a key mediator of oxygen homeostasis. Adv Exp Med Biol 2001;502:365-76.
32. Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ. Regulation of HIF by the von Hipple-Lindau tumor suppressor: implications for cellular oxygen sensing. IUBMB Life 2001;52:43-7.
33. Hon WC, Wilson MI, Harlos K, et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature (Lond.) 2002;417:975-8.
34. Mole DR, Pugh CW, Ratcliffe PJ, Maxwell PH. Regulation of the HIF pathway: enzymatic hydroxylation of the conserved prolyl residue in hypoxia-inducible factor alpha subunits governs capture by the pVHL E3 ubiquitin ligase complex. Adv Enzyme Regul 2002;42:333-47.
35. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in renal cell cancer: relationship to angiogenesis and to the von Hipple-Lindau gene mutation. Cancer Res 2002;62:2957-61.
36. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95:7987-92.
37. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem 2003;278:19575-8.
38. Zhong H, Mabjeesh N, Willard M, Simon J. Nuclear expression of hypoxia-inducible factor 1α protein is heterogeneous in human malignant cells under normoxic conditions. Cancer Lett 2002;181:233-8.
39. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3:363-75.
40. Kim W, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Gen Devel 2003; 13:55-60.
41. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG. Jr. Inhibition of HIF is necessary for tumor suppression by the von-Hippel-Lindau protein. Cancer Cell 2002;1:237-46.
42. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61.
43. Suzuki H, Tomida A, Tsuruo T. Dephosphorylated hypoxia-inducible factor 1 alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 2001; 13:5779-88.
44. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
45. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphotidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002;277:38205-11.
46. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:3995-4004.
47. Blancher C, Moore JW, Robertson N, Harris AL. Effects of ras and von Hipple-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1α, HIF-2α, and vascular endothelial growth factor expression and their regulation by the phosphotidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 2001;61:7349-55.
48. Chan DA, Sutphin PD, Denko NC, Giaccia AJ. Role of hydroxylation in oncogenically stabilized hypoxia-inducible factor-1α. J Biol Chem 2002;277:40112-7.
49. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002;277:27975-81.
50. Arsham AM, Plas DR, Thompson CB, Simon MC. Phosphotidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1α nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem 2002;277:15162-70.
51. Alvarez-Tejado M, Alfranca, A. Aragones J, Vara A, Landazuri MO, del Peso L. Lack of evidence for the involvement of the phophoinositide 3-kinase/ Akt pathway for the activation of hypoxia-inducible factors by low oxygen tension. J Biol Chem 2002;277:13508-17.
52. Mottet D, Dumont V, Deccache Y, et al. Regulation of HIF-1α protein level during hypoxic conditions by the PI3K/Akt/GSK3β pathway in HepG2 cells. J Biol Chem 2003;278:31277-85.
53. Ochel H-J, Gademann G. Heat-shock protein 90: potential involvement in the pathogenesis of malignancy and pharmacological intervention. Onkologie 2002;25: 466-73.
54. Young JC, Moarefi I, Hartl FU. Hsp90: a specialized but essential protein-folding tool. J Cell Biol 2001;154:267-73.
55. Pearl LH, Prodromou C. Structure, function, and mechanism of the Hsp90 molecular chaperone. Adv Protein Chem 2002;59:157-86.
56. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor 1α-degradative pathway. J Biol Chem 2002;277:29936-44.
57. Neckers L, Neckers K. Heat shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Exp Opin Emerging Drugs 2002;7:277-88.
58. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 2000;29:312-22.
59. Welsh SJ, Bellamy WT, Briehl, MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1 alpha protein expression: trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis Cancer Res 2002;62:5089-95.
60. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002;62:4316-24.
61. Shoemaker RH, Scudiero DA, Melillo G, et al. Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr Top Med Chem 2002;2:229-46.
62. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-8.
63. Carmeliet P, Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol 2002;13:39-53.
64. Elson DA, Thurston G, Huang LE, et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α. Genes Dev 2001;15:2520-32.
65. Nathan C. Oxygen and the inflammatory cell. Nature (Lond.) 2003;422:675-6.
66. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 2003;112:645-57.
67. Swinson DE, Jones JL, Richardson D, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003;21:473-82.
68. Peters KB, Wang H, Brown JM, Hiakis G. Inhibition of DNA replication by tirapazamine. Cancer Res 2001;61:5425-31.
69. Peters KB, Brown JM. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 2002;62:5248-53.
70. Hay MP, Gamage SA, Kovacs MS, et al. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J Med Chem 2003;46:169-82.
71. 2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002;60:634-9.
72. Stein W, Subramanian S, Mitchell JB, Krishna MC. EPR imaging of vascular changes in oxygen in response to carbogen breathing. Adv Exp Med Biol 2003;510:231-6.
73. Koch CJ, Evans SM. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv Exp Med Biol 2003;510:285-92.
74. Evans SM, Joiner B, Jenkins WT, Laughlin KM, Lord EM, Koch CJ. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br J Cancer 1995;72: 875-82.
75. Koch CJ, Evans SM, Lord EM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: Analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 1995;72:869-74.
76. Evans SM, Hahn SM, Magarelli DP, Koch CJ. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol 2001;24:467-72.
77. Evans SM, Kachur AV, Shiue CY, et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 2000;41:327-36.
78. Koch CJ, Hahn SM, Rockwell K, Jr., Covey JM, McKenna WG, Evans SM. Pharmacakinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: Implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother. Pharmacol 2001;48:177-87.
79. McCarthy DW, Bass LA, Cutler PD, et al. High purity production and potential applications of copper-60 and copper-61. Nucl Med Biol 1999;26:351-8.